Company Description
Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries.
The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally.
The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States.
It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers.
The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.
Country | United States |
Founded | 2016 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 296 |
CEO | Andres Fajardo |
Contact Details
Address: Bodega 19-b Parque Industrial Tibitoc Ph Tocancipa - Cundinamarca, F8 251017 Colombia | |
Phone | 561-634-7430 |
Website | cleverleaves.com |
Stock Details
Ticker Symbol | CLVR |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001819615 |
CUSIP Number | 186760104 |
ISIN Number | CA1867602031 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Andres Fajardo | Co-Founder, Chief Executive Officer and Director |
Henry R. Hague III | Chief Financial Officer |
Julian Wilches | Chief Regulatory Officer |
Gustavo Escobar | Chief Operating Officer |
Marta Pinto Leite | General Counsel and Corporate Secretary |
Andrew Miller | Head of Business Development |
Camilo Bohorquez | Head of Colombia |
Caroline Kliess | Managing Director of Germany |
Jackie Keshner | Investor Relations Executive |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 19, 2024 | AW | Amendment Withdrawal Request |
Apr 17, 2024 | 8-K | Current Report |
Apr 16, 2024 | POS AM | Post-Effective amendments for registration statement |
Apr 15, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
Apr 1, 2024 | 10-K | Annual Report |
Apr 1, 2024 | 8-K | Current Report |
Mar 27, 2024 | 424B3 | Prospectus |
Mar 27, 2024 | 8-K | Current Report |
Feb 1, 2024 | 424B3 | Prospectus |
Feb 1, 2024 | 8-K | Current Report |